OSSIO Launches Small OSSIOfiber® Suture Anchors, Expanding Best-in-Class Portfolio of Bio-Integrative, Metal-Free Implants to Improve Soft Tissue Fixation

‘The future of orthopedics’

WOBURN, Mass.–(BUSINESS WIRE)–#biointegrative–OSSIO Inc., a fast-growing medical technology company focused on evolving orthopedic surgery with bio-integrative, metal-free implants, recently expanded its best-in-class soft-tissue fixation portfolio with the launch of OSSIOfiber® 2.5mm Suture Anchors, which promise to improve several surgical procedures, including Brostrom repair for lateral ankle instability.

“With these new small OSSIOfiber Suture Anchors, I can approach a familiar procedure with the same technique I’ve always trusted, only now I’m using a smaller, stronger, smarter material that I believe is the future of orthopedics,” Thomas Philip San Giovanni, M.D., a board-certified orthopedic surgeon affiliated with Baptist Health South Florida, said. “Outcomes with this novel material aren’t just equivalent, they’re better in my experience.”

• Smaller. OSSIOfiber 2.5mm Suture Anchors are designed for procedures like Brostrom repair, a standard surgery to fix lateral ankle instability.
• Stronger. These new fixation implants offer 55% greater pull-out strength over the market-leading 2.4mm bio-composite suture anchor.
• Smarter. As with the rest of the company’s expanding product portfolio, OSSIOfiber Suture Anchors feature a novel material engineered without metal to integrate into bone, leaving a more natural orthopedic landscape with minimal risk of adverse reactions.

Challenging fixation standard while accommodating procedural standard

The device’s physical design supports an array of standard surgical techniques for fixating suture or soft tissue with a procedural workflow and instrumentation set that are both familiar and efficient, including drill bits and a slotted drill guide for easy drilling and anchor insertion. In addition, its versatile configuration options—specifically, unloaded and pre-loaded devices—allow for technical flexibility and respect varying surgeon preferences.

“In launching our latest OSSIOfiber platform, we’ve brought to market the first small, fully bio-integrative suture anchor, which outperforms current options for lateral ankle instability and other repairs,” OSSIO CEO Brian Verrier explained. “With this anchor, surgeons can perform these procedures with less impact and better results for patients, while adding fixation strength. The device also rounds out our best-in-class line of implants for soft tissue fixation.”

Indications for use: OSSIOfiber® Suture Anchors (2.5–3.5mm range) are intended to be used for suture or tissue fixation in the foot, ankle, knee, hand, wrist, elbow, and shoulder, in adults and children (2–12 years) and adolescents (12–21 years) in which growth plates have fused or in which growth plates will not be crossed by fixation, in a variety of specific orthopedic indications as follows:

• Foot/Ankle. Lateral Stabilization, Medial Stabilization, Achilles Tendon Repair, Metatarsal Ligament Repair, Hallux Valgus Reconstruction, Digital Tendon Transfers, Mid-foot Reconstruction
• Knee. Medial Collateral Ligament Repair, Lateral Collateral Ligament Repair, Patellar Tendon Repair, Posterior Oblique Ligament Repair, Iliotibial Band Tenodesis, Joint Capsule Closure
• Hand/Wrist. Scapholunate Ligament Reconstruction, Carpal Ligament Reconstructions, Repair/Reconstruction of Collateral Ligaments, Repair of Flexor and Extensor Tendons at the PIP, DIP and MCP joints for all digits, Digital Tendon Transfers
• Elbow. Biceps Tendon Reattachment, Ulnar or Radial Collateral Ligament Reconstruction, Lateral Epicondylitis Repair (Tennis Elbow)
• Shoulder. Rotator Cuff Repairs, Bankart Repair, SLAP Lesion Repair, Biceps Tenodesis, Acromio-Clavicular Separation Repair, Deltoid Repair, Capsular Shift or Capsulolabral Reconstruction

About OSSIOfiber implants

Based on Intelligent Bone Regeneration Technology, OSSIOfiber implants combine unparalleled mechanical strength and natural healing in a bio-integrative design. Their proprietary mineral fiber matrix enables rapid bone in-growth, regeneration, and replacement—a new way for orthopedic surgeons to restore stability and mobility while leaving nothing permanent behind.

OSSIOfiber implants represent the first credible alternative to metal, absorbable, and allograft fixation devices. The most significant advance in orthopedic fixation technology in more than 100 years, this novel medical technology has the potential to address an increasingly wide array of surgical applications due to the proprietary “know-how” to manufacture limitless variations. Looking ahead, the company intends to continue developing additional applications for OSSIOfiber implants in all major segments of orthopedics.

Notably for U.S. healthcare providers and payors, OSSIOfiber implants utilize existing reimbursement codes and surgical techniques. Their uptake continues to grow because of strong patient and surgeon preference to avoid the concerns and complications of metal fixation implants. Through June 2025, more than 50,000 OSSIOfiber implants have been used in the U.S.

About OSSIO Inc.

OSSIO is an orthopedic fixation company committed to transforming the surgical experience for patients, physicians, providers, and payors. The company’s vision is to provide the first credible replacement for metal implants in the multibillion-dollar global orthopedic fixation market with OSSIOfiber Intelligent Bone Regeneration Technology. Founded in 2014, OSSIO conducts product development in Caesarea, Israel, and commercial operations from Woburn, Mass. For more information about the company and OSSIOfiber implants, visit www.ossio.io.

Disclaimer: Forward-looking statements in this news release are based on estimates and assumptions of OSSIO management and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Contacts

Joe McGrath

Scope Strategic Communications

contactmcgrath@scopestrategic.com
+1-612-819-6421